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Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease in which prostaglandin E2 (PGE2) displays
an important pathogenic role. The enzymes involved in its synthesis are highly expressed in the inflamed
synovium, while little is known about 15- prostaglandin dehydrogenase (15-PGDH) that metabolizes PGE2. Here we
aimed to evaluate the localization of 15-PGDH in the synovial tissue of healthy individuals or patients with
inflammatory arthritis and determine the influence of common RA therapy on its expression.
Methods: Synovial tissue specimens from healthy individuals, psoriatic arthritis, ostheoarthritis and RA patients
were immunohistochemically stained to describe the expression pattern of 15-PGDH. In addition, the degree of
enzyme staining was evaluated by computer analysis on stained synovial biopsies from two groups of RA patients,
before and after RA specific treatment with either intra-articular glucocorticoids or oral methotrexate therapy.
Prostaglandins derived from the cyclooxygenase (COX) pathway were determined by liquid-chromatography mass
spectrometry in supernatants from interleukin (IL) 1b-activated fibroblast-like synoviocytes (FLS) treated with
methotrexate.
Results: 15-PGDH was present in healthy and inflamed synovial tissue, mainly in lining macrophages, fibroblasts
and vessels. Intra-articular glucocorticoids showed a trend towards reduced 15-PGDH expression in RA synovium
(p = 0.08) while methotrexate treatment left the PGE2 pathway unaltered both in biopsies ex vivo and in cultured
FLS.
Conclusions: Early methotrexate therapy has little influence on the expression of 15-PGDH and on any of the PGE2
synthesizing enzymes or COX-derived metabolites. Thus therapeutic strategies involving blocking induced PGE2
synthesis may find a rationale in additionally reducing local inflammatory mediators.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune
disease characterized by inflammation and extensive pro-
liferation within the joint synovial tissue and by recruit-
ment and activation of immune cells and subsequent
cartilage and bone destruction. Rheumatoid joint displays
an activated prostaglandin E2 (PGE2) pathway, and there
are high levels of this mediator in the synovial fluid and
strong expression in the synovium of its synthesizing
enzymes, microsomal prostaglandin E2 synthase 1
(mPGES-1) as well as cyclooxygenase (COX) 1 and 2 [1].
Wheres COX-1 is considered a constitutive enzyme pre-
sent under basal conditions, COX-2 is inflammation-
induced [2] and co-localizes with mPGES-1 in the synovial
tissue [3]. The deleterious role of PGE2 in the pathogenesis
of RA has already been established and occurs through
multiple mechanisms. PGE2 sustains inflammatory path-
ways by promoting expansion of auto-aggressive T helper
17 (Th17) cells [4], increases angiogenesis within the pro-
liferating synovium, and regulates cartilage and bone
metabolism by stimulation of osteoclast and matrix metal-
loproteinase activity. Pro-inflammatory cytokines, such as
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tumor necrosis factor (TNF) and interleukin-1-beta (IL-
1b), that orchestrate the pathological events in this disease
are known inducers of mPGES-1 and COX-2 expression
[5].
The levels of PGE2 are determined not only by its synth-
esis but also by the rate of degradation. Most of the pros-
taglandin inactivation occurs through the action of
15-hydroxyprostaglandin dehydrogenase (15-PGDH),
which converts PGE2 to a metabolite with greatly reduced
biological activity [6] and is thus the main mechanism for
PGE2 clearance. 15-PGDH is ubiquitously expressed in
most mammalian tissues [6]. In humans, IL-6 [7] and
transforming growth factor-beta (TGFb) regulate its
expression in prostate and colon cancer, respectively,
whereas TNF downmodulates it in colonocytes [8]. In
addition, mediators controlling PGE2 formation recipro-
cally stimulate COX-2 while reducing 15-PGDH expres-
sion [9]. 15-PGDH decrease or loss was demonstrated in
gastric [10], lung [11], and thyroid [12] tumors and results
in increased malignant cell proliferation and cancer pro-
gression. In addition, reduced expression of 15-PGDH
contributes to the elevated PGE2 levels observed in the
systemic inflammatory response [13] or in the inflamed
mucosa of patients with inflammatory bowel disease [8].
Recent reports demonstrated 15-PGDH synthesis in
mouse articular chondrocytes and an inverse regulation
of mPGES-1 and 15-PGDH by adipocyte-derived factors
in these cells, resulting in boosted PGE2 levels [14].
Also, mechanical stress increases 15-PGDH mRNA
expression in this system [15]. However, the presence
and localization of this enzyme in human synovial tissue
remain largely unknown.
Intra-articular glucocorticoids (GCs) are often used as
efficient adjuvant therapy in RA to control for local
inflammation. One of the mechanisms by which they
achieve their anti-inflammatory effect relies also on inhi-
bition of synovial mPGES-1 and COX-2 expression and
formation of PGE2 [3]. Earlier reports evaluating the
influence of dexamethasone on 15-PGDH demonstrated
either induced expression in A549 cells [16] or inhibi-
tion of in vitro stimulated enzyme expression in a
monocyte cell line [17].
In patients with RA, one of the most efficient drugs
used in most cases as first-line therapy is methotrexate
[18]. Its interference with the cellular folate metabolism
results in immunosuppressive effects by inhibition of
synovial inflammatory cell proliferation and enhance-
ment of adenosine release. The influence of methotrex-
ate on PGE2 production appears controversial; reports
demonstrate inhibitory action in whole blood of patients
with RA [19] and in fibroblast-like synoviocytes (FLSs)
[20], but studies also point to no effect on PGE2 release
by FLSs [21,22].
We undertook this study to investigate the distribu-
tion of 15-PGDH in synovial tissue and the effects of
methotrexate therapy on the synovial expression of the
PGE2 pathway enzymes in patients with newly diag-
nosed RA and in vitro in cultured FLSs. Moreover, we
analyzed the change in expression pattern for 15-PGDH
induced by local administration of GCs known to have
potent anti-inflammatory properties.
Materials and methods
Patients and clinical data
Synovial biopsies were collected at the time of surgical
joint replacement from eight patients with RA and five
with ostheoarthritis (OA). In addition, synovial samples
from three healthy individuals and three patients with
psoriatic arthritis (PsA) were obtained by arthroscopy.
The biopsies were used for detection and cellular locali-
zation of synovial 15-PGDH.
To investigate the effects of anti-rheumatic treatment
on the enzymes of the PGE2 cascade, synovial biopsies
were collected from two cohorts of patients. In the first
group, 13 patients with newly diagnosed RA were
enrolled; the median time period since diagnosis was 7
days, and the median time since the beginning of symp-
toms was 6.5 months. Table 1 illustrates the clinical and
laboratory data of the patient cohort. These patients had
active disease with a Disease Activity Score in 28 joints
(DAS28) of greater than 3.2 (mean of 5.7). All patients
fulfilled the American College of Rheumatology criteria
for RA [23]. At baseline and 1 year after inclusion in the
Table 1 Demographic, clinical, and laboratory data of the
methotrexate study cohort
Characteristics of cohort Value
Number of patients 13
Median age (range), years 56 (32-78)
Number of males/females 4/9
Median interval from diagnosis (range), days 7 (1-25)
Median duration of symptoms (range), months 6.5 (2-12)
ACPA-positive patients, number (percentage) 6 (46)
Rheumatoid factor-positive patients, number (percentage) 9 (69)
Number of patients taking oral corticosteroids 2
Number of patients taking NSAIDs 10
Median duration between biopsies (range), days 58 (45-70)
Number of patients presenting erosions (percentage)
At baseline 2 (15)
After 1 year 7 (53)
Mean DAS28 (minimum, maximum)
At baseline 5.7 (3.9, 6.7)
After 3 months 3.8 (1.8, 5.8)
ACPA, anti-cyclic citrullinated peptide antibody; DAS28, Disease Activity Score
in 28 joints; NSAID, non-steroidal anti-inflammatory drug.
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study, plane radiographs of the affected joint were evalu-
ated for the presence of erosions. DAS28 was assessed at
baseline and at a median of 3 months after treatment
initiation. Patients were assigned to start methotrexate
therapy with an initial dosage of 10 mg/week, which was
increased in a stepwise manner to achieve the final
dosage of 20 mg/week after 3 weeks. Synovial biopsies
were obtained by arthroscopy from the same inflamed
joint before methotrexate initiation and after a median
of 8 weeks. Oral non-steroidal anti-inflammatory drugs
(NSAIDs) and GCs in doses of up to 10 mg daily were
allowed, as was a maximum of three intra-articular GC
injections in joints other than the one biopsied.
In the second group, 10 patients who had RA and
active knee arthritis were recruited to the study. The clin-
ical features of this patient group were published pre-
viously [24]. All patients in the second group received an
intra-articular injection of 40 mg of triamcinolone hexa-
cetonide. Synovial biopsies were obtained prior to and a
median of 10 days after treatment. All other anti-rheu-
matic medication was kept unchanged 2 weeks before the
first arthroscopy and for the rest of the study period. All
investigations were approved by the ethics committee of
the Karolinska University Hospital, and participants gave
written informed consent to participate in the study.
Immunohistochemical evaluation
Frozen serial biopsy sections were fixed in 2% formalde-
hyde, and immunohistochemical staining was performed
by using rabbit polyclonal anti-serum raised toward
mPGES-1 [1], rabbit polyclonal anti-15-PGDH (Novus
Biologicals, Littleton, CO, USA) and anti-COX-1 (Cayman
Chemical Company, Ann Harbor, MI, USA), and mouse
monoclonal anti-COX-2 (CX229; Cayman Chemical Com-
pany) antibodies in accordance with a published protocol
[25]. Stained sections were quantitatively evaluated by
computer-based image analysis, and results were
expressed as the percentage of positive stained area versus
total tissue staining. For immunofluorescence experiments,
sections were incubated with a mixture of primary antibo-
dies against 15-PGDH and cell markers for macrophages
(CD163, clone Ber-MAC3), fibroblasts (prolyl-4-hydroxy-
lase, clone 5B5), B cells (CD20, clone L26) (all from Dako-
Cytomation, Glostrup, Denmark), T cells (CD3, SK7; BD
Biosciences, San Jose, CA, USA), and endothelial cells
(CD31, clone EN4; Novakemi, Handen, Sweden) followed
by the addition of secondary antibodies conjugated to
Alexa 546 or Alexa 483 (Invitrogen Corporation, Carlsbad,
CA, USA).
In vitro culture of fibroblast-like synoviocytes and
measurement of prostaglandins
Commercially available FLSs (Dominion Pharmakine,
S.L., Bizkaia, Spain) from patients with RA were grown
in Dulbecco’s modified Eagle’s medium supplemented
with 10% human serum and penicillin streptomycin
(100 units/mL) in a humidified atmosphere containing
5% CO2 at 37°C. When reaching confluence, cells were
passaged by gentle trypsinization and used between pas-
sages 4 and 6. The cells were incubated for 48 hours
with 10 ng/mL IL-1b (R&D Systems, Abingdon, UK) in
the presence or absence of 10 or 250 μM methotrexate.
Unstimulated cells were used as controls. After treat-
ment, supernatants were collected and frozen at -20°C
until analyzed. Cells were trypsinised, washed twice in
phosphate-buffered saline (PBS), and harvested for sub-
sequent Western blot analysis.
Prostaglandin profiling of the primary prostaglandins
(PGE2, PGD2, and PGF2a) and of the metabolites of PGI2
and tromboxane A2 (TxA2) - 6-keto PGF1a and TxB2,
respectively - was accomplished by using liquid chroma-
tography tandem mass spectrometry (LC-MS-MS). Cell
culture supernatants were extracted with an Oasis HLB
Extraction Plate (Waters Corporation, Milford, MA,
USA) and analyzed by high-performance liquid chroma-
tography by using Waters 2795 HPLC (Waters Corpora-
tion) coupled to a triple quadrupole mass spectrometer
(Acquity TQ Detector; Waters Corporation). PGE2,
PGD2, PGF2a, TxB2, 6-keto-PGF1a, and their correspond-
ing deuterated standards were detected by using multiple
reaction monitoring and quantified by using internal
standard methodology and QuanLynx software (Waters
Corporation).
Western blot analysis of enzymes
Cells were harvested after the different treatments and
protein was extracted by using cell lysis buffer (Pierce,
Rockford, IL, USA) in accordance with the instructions
of the manufacturer. Total protein concentration was
determined by using the NanoDrop technique, and equal
amounts of protein were separated on 4% to 12% NuPage
polyacrylamyde gels (Invitrogen Ltd., Paisley, UK). The
resolved proteins were blotted onto polyvinylidene fluor-
ide membranes (Pall Life Sciences, Pensacola, FL, USA),
which were further blocked in PBS-Tween-20 buffer con-
taining 5% (wt/vol) non-fat dry milk for 1 hour at room
temperature. Incubation with primary antibodies rabbit
polyclonal anti-serum against mPGES-1, rabbit polyclo-
nal anti-COX-2 (Cayman Chemical Company), rabbit
polyclonal anti-15-PGDH (Cayman Chemical Company),
or mouse monoclonal anti-b-actin (NeoMarkers, Free-
mont, CA, USA) was performed overnight at 4°C. After
washing in 0.05% TTBS (Tris-Tween-buffered saline), the
membranes were incubated with horseradish peroxidase-
linked anti-rabbit IgG from donkey (GE Healthcare,
Stockholm, Sweden), washed extensively in 0.1% TTBS,
and finally visualized by a chemiluminiscence detection
kit (Thermo Scientific, Rockford, IL, USA) on film
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(Amersham Hybond; GE Healthcare, Buckinghamshire,
UK).
Statistical analysis
For statistical analysis of the methotrexate and GC
cohorts, we used the Wilcoxon test for paired samples,
followed by Bonferroni corrections for multiple compar-
isons, whereas in vitro data were analyzed by the Mann-
Whitney test for unpaired samples. P values of less than
0.05 were considered significant.
Results
Distribution of 15-PGDH in rheumatoid arthritis synovial
tissue
All RA biopsy samples analyzed displayed 15-PGDH
expression (Figure 1a). Its presence in RA synovial tissue
was prominent in the synovial lining but also in scat-
tered sublining macrophages and inflammatory infil-
trates as well as vessels. Expression of 15-PGDH among
patients was, nonetheless, variable; staining was strong
and extensive in some patients and weak and confined
mostly to the synovial membrane in others. In addition,
the enzyme was present, albeit to a lesser extent, in
healthy synovial tissue and in synovium from patients
with OA and those with PsA (Figure 1b-d). Similarly to
RA, the enzyme was found mainly in the lining layer in
healthy tissue, PsA, and OA, although the expression
was somewhat weaker in the lining synovial cells of
healthy individuals compared with RA.
Most 15-PGDH-expressing cells were identified by
double-immunofluorescence as CD163-positive synovial
macrophages and fibroblasts in RA synovium (Figure 2a
left and middle panels). In addition, most sublining ves-
sels stained positively for 15-PGDH in endothelial cells
(Figure 2 right panel) whereas CD20-positive B cells and
CD3-positive T cells essentially lacked 15-PGDH
enzyme (data not shown).
Clinical evaluation and response to treatment
Out of the 13 patients included in the methotrexate
study cohort, seven were responders, defined as those
who had good or moderate response to treatment
according to the European League Against Rheumatism
(EULAR) criteria, and six were non-responders. The
overall mean DAS28 decreased significantly to 3.8 after
3 months of treatment. All patients receiving intra-
articular GCs were clinical responders as assessed by the
local clinical examination of the joint and macroscopic
evaluation of the local inflammation during the second
arthroscopy.
Figure 1 Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy and inflamed synovial tissue. Immunohistochemical
staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) and patients
with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d).
Gheorghe et al. Arthritis Research & Therapy 2012, 14:R121
http://arthritis-research.com/content/14/3/R121
Page 4 of 9
Effects of intra-articular steroid therapy on the expression
of 15-PGDH in rheumatoid arthritis synovial tissue
We have earlier reported that intra-articular GC treat-
ment downregulated the expression of PGE2-synthesizing
enzymes in the rheumatoid synovium. Here, our results
demonstrated that local GC therapy resulted in reduced
expression of 15-PGDH in nine patients but that two
patients showed increased values after therapy (Figure
2b). Overall, although no statistical difference (P = 0.08)
was detected before or after local GC injection, there was
a clear trend toward diminished enzyme expression fol-
lowing therapy.
Effects of methotrexate therapy on the expression of 15-
PGDH and related enzymes in rheumatoid arthritis joint
We then studied the effect of oral methotrexate therapy
on 15-PGDH and found that 8 weeks of oral methotrexate
treatment did not significantly change the synovial expres-
sion level of 15-PGDH (Figure 2c). As the local PGE2 pro-
duction is determined by its biosynthesis and degradation,
we also examined whether methotrexate affects the bio-
synthetic enzymes. No effects of methotrexate on synovial
expression of mPGES-1, COX-1, and COX-2 were
detected (Figure 3). Stratifying patients according to
response to treatment, presence of anti-cyclic citrullinated
peptide antibodies, or erosion progression did not show
any significant difference in enzyme expression between
or within the groups (data not shown). We also found a
similar overall staining pattern for PGE2-related enzymes
irrespectively of NSAID treatment (data not shown).
In unstimulated in vitro cultured FLSs, low levels of
PGE2 formation were mirrored by undetectable expression
of COX-2 and mPGES-1 (Figure 4a, b). Still, FLSs dis-
played low 15-PGDH amounts even in basal conditions,
Figure 2 Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue and the effects of
anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells and cell
marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, and endothelial cell CD31. Merged images display double-stained
cells in yellow. Original magnification: ×400. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical
positive (brown) staining for 15-PGDH before and after intra-articular treatment with glucocorticoids (b) and before and 8 weeks after initiation
of methotrexate therapy (c) (hematoxilin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial
tissue before and after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area.
GC, glucocorticoids; Mtx, methotrexate.
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and this is in line with the presence of this enzyme in most
tissues. As expected, IL-1b determined a strong increase in
PGE2 production along with upregulation of enzyme
expression. The increase in 15-PGDH expression follow-
ing IL-1b stimulation was, however, modest in comparison
with the dominant upregulation of the synthesizing
enzymes mPGES-1 and COX-2, explaining the net effect
of increased PGE2 synthesis. However, the addition of
methotrexate in either low or high concentration did not
abrogate the IL-1b-induced effects on any studied enzyme
expression or the PGE2 formation. Furthermore, analysis
of the prostanoid profile by LC-MS-MS in supernatants
Figure 3 Effects of methotrexate on the expression of prostaglandin E2 biosynthetic enzymes in rheumatoid synovium .
Immunohistochemical evaluation of positive staining for microsomal prostaglandin E2 synthase 1 (mPGES-1), cyclooxygenase 1 (COX-1), and
COX-2 in synovial tissue biopsies before and 8 weeks after initiation of methotrexate treatment. Results are expressed as a percentage of the
positive stained area versus the total tissue area.
Figure 4 Effects of methotrexate on the prostaglandin production by rheumatoid arthritis fibroblast-like synoviocytes (FLSs). Synovial
fibroblasts were left untreated or activated with 10 ng/mL interleukin-1-beta (IL-1b) in the absence or presence of 10 or 250 μM methotrexate
for 48 hours. After treatment, total protein was isolated and assayed for enzyme expression, while b-actin was used as loading control.
Supernatants were analyzed for prostanoid content by using liquid chromatography tandem mass spectrometry. (a) Analysis of prostaglandin E2
(PGE2) formation in control and IL-1b-stimulated FLSs with or without methotrexate. (b) Representative Western blot results show expression of
microsomal prostaglandin E2 synthase 1 (mPGES-1), cyclooxygenase 2 (COX-2), and 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid
arthritis FLSs. (c) Analysis of PGD2, PGF2a, and the metabolites of PGI2 and TxA2 (6-keto PGF1a and TxB2, respectively) in culture supernatants
indicates the amount formed after 48 hours of incubation. Horizontal lines indicate median values, and whiskers indicate range values (n = 4).
Ctrl, control; Mtx, methotrexate; Tx, tromboxane.
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from stimulated and unstimulated FLSs showed that
methotrexate had no influence on the formation of any of
the lipid mediators derived from the COX pathway, as
demonstrated by detection of PGE2, PGD2, and PGF2a
and metabolites of PGI2 or TxA2 (Figure 4c).
Discussion
The contribution of the PGE2 pathway to the RA patho-
genic process has been well established, and most studies
have focused on PGE2 and its inflammation-dependent
synthesizing enzymes. However, 15-PGDH, the enzyme
responsible for the degradation of PGE2, has received little
attention in this context, although its level of expression
ultimately determines the availability of PGE2.
We described here for the first time the distribution pat-
tern of 15-PGDH in synovial tissue in both pathological
(inflammatory) and healthy conditions. 15-PGDH was pre-
sent in patients with RA and was localized mostly in the
lining macrophages and sublining fibroblasts and vessels.
This finding is in agreement with localization of the
mPGES-1 and COX enzymes in RA synovial tissue [1],
indicating the possibility for local regulation and balance
of formation and removal of PGE2. An alternative view is
that, in an effort to overcome the high prostaglandin bur-
den in RA, 15-PGDH expression increases as a protective
mechanism. Furthermore, the enzyme was present in OA
and PsA synovium, and this is in line with the association
of these conditions with variable degrees of inflammation
in synovial tissue. To a lesser extent, we also identified
15-PGDH in the synovial lining of healthy individuals,
indicating constitutive formation of PGE2 in synovial tis-
sue. Expression of PGE2 pathway enzymes has been
reported in non-inflammatory conditions in kidney [26]
and muscle [27], suggesting a possible role for basal PGE2
production in local tissue homeostasis.
Intra-articular GCs relieve local symptoms in the
inflamed RA joint and are successfully used as add-on
therapy to control for occasional bouts of inflammation.
In this study, we demonstrated that GC injections may
decrease the expression of 15-PGDH in synovial tissue
that in turn, may promote local accumulation of PGE2.
However, previous data from our group showed reduced
expression of mPGES-1 and COX after local GC treat-
ment [3], resulting in a diminished PGE2 generation.
Thus, the attenuated 15-PGDH expression observed here
may reflect simply a negative feedback induced by low
PGE2 availability. Also, although PGE2 has a pivotal role in
bone remodeling and degradation [28], complete removal
of PGE2 may not be beneficial as there is evidence for a
protective role for basal PGE2 in the resolution phase of
inflammation [29-31] as well as for suppression of B-cell
proliferation by PGE2 [32]. Furthermore, it is important to
keep in mind that 15-PGDH, though the key enzyme for
catabolism of prostaglandins, is also involved in degrada-
tion of lipoxins [33], with essentially opposed activity in
the inflammatory milieu. As such, the lack of effect or
trend toward decreased 15-PGDH reported here by GC
may, in fact, contribute to preserving anti-inflammatory
lipid mediators.
Given the limitation of the analytical system used in our
study, we cannot rule out that the change in positive stain-
ing may be the result of a decrease in the number of
inflammatory cells expressing the enzymes rather than an
actual reduction in cellular expression. Data from a pre-
vious study demonstrated that intra-articular corticosteroid
therapy reduced the number of synovial T lymphocytes but
that the number of macrophages remained unchanged
[34]. Since mPGES-1, 15-PGDH, and the COX enzymes
are detected mainly in the macrophage and fibroblast
populations but are essentially lacking in synovial lympho-
cytes, it is reasonable to assume that the changes we detect
may be due to both reduced cellular enzyme formation
and reduced inflammatory cell infiltration.
Despite being the first line of therapy for RA [35] and
highly efficient in many patients, oral methotrexate
showed no significant influence on the enzymes coordinat-
ing PGE2 metabolism. Image analysis of mPGES-1 expres-
sion, though not detecting any statistically significant
change, showed that only four out of 13 patients displayed
an increased mPGES-1 staining but that in all others
methotrexate decreased the positive stained area. Thus, we
cannot exclude an actual effect of the given therapy
toward decreased mPGES-1, had we had a larger study
cohort. On the other hand, the lack of effect on the 15-
PGDH levels seen in our group of newly diagnosed sub-
jects suggests local persistence of PGE2 in these patients.
In fact, PGE2 availability despite methotrexate therapy
could explain the progression in joint erosion seen in
some of the responder patients. It is well known that
methotrexate, through folate-dependent biosynthetic
blockade, causes upstream accumulation of adenosine that
turns on anti-inflammatory pathways by acting predomi-
nantly on A2A and A3 receptors [36]. In fact, experimen-
tal and clinical data suggest that the adenosine-mediated
anti-inflammatory effect is the most prominent mechan-
ism for low-dose methotrexate efficiency in RA. In this
sense, inhibition of TNF [37] and IL-1b [38] actions and
enhanced IL-10 [39] production were reported as indirect
effects through adenosine release. Several reports suggest
that methotrexate, administered either in vivo in animal
models of arthritis [40] or added in vitro in different cell
systems such as rat peritoneal macrophages [41] and
human rheumatoid synoviocytes [20], may have inhibitory
effects on PGE2 production. There is, however, evidence
that methotrexate may fail to elicit a change in PGE2 in
human fibroblasts [22,42]. Although study conditions and
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systems differ in the aforementioned studies, a clear and
definite effect of methotrexate on the prostaglandin path-
way in synovium-derived cells is not apparent. Our in
vitro results demonstrated that, in RA FLSs, methotrexate
had no influence on the PGE2 pathway or on any of the
COX-derived lipid mediators. The increase in 15-PGDH
expression following IL-1b treatment of synovial fibro-
blasts may be secondary to the high PGE2 amount formed
under these circumstances, as PGE2 itself may induce 15-
PGDH mRNA expression [43].
An earlier study evaluating synovial biopsies after 4
months of methotrexate treatment indicated that the
macrophages and lymphocyte populations are reduced
in the RA synovium [44]. Recent data from the same
cohort of patients as the one used in our study demon-
strated that 8 weeks of oral methotrexate therapy
reduced the number of synovial CD3-positive lympho-
cytes and, to a lesser extent, the CD68-positive macro-
phages (Shankar Revu, submitted manuscript). Although
lining and sublining macrophages highly express the
enzymes involved in PGE2 formation, we found no sig-
nificant influence exerted by methotrexate in our study.
However, our study was designed to detect early
changes in the synovium after the start of therapy and
thus additional effects may become evident later on.
Conclusions
15-PGDH is present in synovial tissue in conditions
associated with inflammatory responses, such as OA,
PsA, and RA, in a manner similar to that of the PGE2-
synthesizing enzymes. Local GC treatment seems to
reduce its expression, whereas oral methotrexate therapy
exerts little influence in synovial tissue or in FLSs in
vitro. Together, these results suggest that the inflamma-
tion-induced PGE2 pathway may not be properly tar-
geted by anti-rheumatic treatment but instead persists
and contributes to perpetuating inflammatory circuits in
the rheumatoid synovium. As such, therapeutical
attempts aiming at blocking the excessive production of
PGE2 may be justified in order to offer additional benefit
in reducing synovial inflammation and damage.
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